A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Wong, R Cunningham, D Barbachano, Y Saffery, C Hickish, T Mudan, S Brown, G Khan, A Wotherspoon, A
Wong, R
Cunningham, D
Barbachano, Y
Saffery, C
Hickish, T
Mudan, S
Brown, G
Khan, A
Wotherspoon, A
Citations
Altmetric:
Abstract
Perioperative chemotherapy improves outcome in resectable colorectal liver-only metastasis (CLM). This study aimed to evaluate perioperative CAPOX (capecitabine-oxaliplatin) plus bevacizumab in patients with poor-risk CLM not selected for upfront resection.
Description
Date
2011-09
Publisher
Collections
Keywords
Type
Article
Citation
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. 2011, 22 (9):2042-8 Ann Oncol